三生国健(688336) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥186,755,665.94, representing a 25.09% increase compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥8,366,397.96, while the net profit for the year-to-date period decreased by 79.40% to ¥1,177,032.01[7]. - Total revenue for the first three quarters of 2022 was ¥527,354,132.76, a decrease of 16.06% compared to ¥628,020,782.36 in the same period of 2021[26]. - Net profit for the third quarter of 2022 was -¥5,995,873.26, an improvement from -¥10,550,259.89 in the same quarter of 2021[29]. - The total comprehensive income attributable to the parent company for Q3 2022 was ¥15,032,660.22, compared to ¥7,164,704.58 in Q3 2021, showing an increase[30]. Research and Development - Research and development (R&D) expenses totaled ¥72,419,985.97 in Q3 2022, a decrease of 31.39% year-on-year, and accounted for 38.78% of revenue, down 31.92 percentage points[9]. - The company focused its R&D spending on self-immune fields, leading to a reduction in expenses for other areas, which contributed to the overall decrease in R&D costs[12]. - Research and development expenses for the first three quarters of 2022 amounted to ¥216,576,998.56, a decrease of 31.85% from ¥317,787,448.27 in 2021[26]. - The company has a significant focus on R&D, with ongoing investments in new product development and market expansion strategies[20]. Assets and Liabilities - The total assets at the end of Q3 2022 were ¥5,044,377,769.75, reflecting a 3.18% increase from the end of the previous year[9]. - The total liabilities increased to ¥487,588,673.99 in 2022 from ¥349,731,365.38 in 2021, representing a growth of 39.5%[26]. - The total current assets increased to RMB 3,010,797,962.82, up from RMB 2,871,558,476.65, indicating a growth of approximately 4.9%[22]. - The total non-current assets slightly increased to RMB 2,033,579,806.93 from RMB 2,017,273,633.62, a growth of approximately 0.8%[22]. - The total equity attributable to shareholders at the end of Q3 2022 was ¥4,566,423,460.47, a slight increase of 0.55% from the previous year[9]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥140,442,228.33, indicating an increase due to improved sales collection[9]. - The net cash flow from operating activities for the first three quarters of 2022 was ¥140,442,228.33, a significant improvement from a negative cash flow of ¥148,252,249.96 in the same period of 2021[33]. - The net cash flow from investing activities for Q3 2022 was -¥399,764,887.91, compared to -¥76,069,736.51 in Q3 2021, reflecting increased investment outflows[33]. - The total cash inflow from investment activities for the first three quarters of 2022 was ¥4,657,265,367.56, significantly higher than ¥2,458,756,568.50 in the same period of 2021[33]. - The company received cash from financing activities amounting to ¥152,297,520.00 in Q3 2022, with a net cash flow from financing activities of ¥151,949,325.55[33]. Shareholder Information - The number of shareholders at the end of the reporting period was 11,861, with the largest shareholder holding 92% of the shares[16].